Share Price:

APNASPENAspen Pharmacare Hldgs14888213 (1.45%)
Our Response to Covid
Country Sites

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

Author: bpc

Aspen Global acquires Australian product portfolio for R2.2 billion

The Aspen Group (“Aspen”) is pleased to announce that Aspen Global Incorporated (“Aspen Global”), a wholly owned subsidiary of Aspen Holdings, has reached agreement with GlaxoSmithKline plc (“GSK”) for the acquisition of a portfolio of 25 established pharmaceutical products (“the Products”) which are distributed in Australia (“the Transaction”). The Transaction consideration is GBP 172 million (ZAR 2.2 billion at ZAR 12.72/GBP) based upon a completion date of 31 October 2012 and is subject to minor reduction should completion be delayed beyond this date. The Transaction is subject to the following conditions precedent: The approval of the Australian competition authorities; and The approval of the Australian Foreign Investment Review Board. The effective date of the Transaction will be the last business day of the calendar month in which the last of the applicable conditions precedent is fulfilled. Existing manufacturing arrangements for the Products will be assumed by Aspen Global. Aspen Global intends to appoint Aspen Australia to distribute the Products. Funding The Transaction will be funded from new offshore debt facilities. Arrangements for the raising of the new debt have been settled, but remain subject to documentation being completed. Financial effects The unaudited pro-forma financial effects set out in the tables below have been prepared to assist Aspen Holdings shareholders to assess the impact of the Transaction on the earnings per share (“EPS”) and diluted EPS, headline EPS (“HEPS”) and diluted headline EPS, diluted normalised HEPS and the net asset value (“NAV”) and the tangible NAV (“NTAV”) per Aspen Holdings ordinary share as at 31 December 2011 and for the interim period then ended. It has been assumed for the purposes of the pro-forma financial effects that the Transaction took place with effect from 1 July 2011 for Statement of Comprehensive Income purposes and at 31 December 2011 for Statement of Financial Position purposes. The pro-forma financial effects have been prepared for illustrative purposes only and, because of their nature, they may not fairly present Aspen’s restated financial position at 31 December 2011 and the restated results of its operations for the six months then ended. The Directors of Aspen Holdings are responsible for the preparation of the financial effects which have not been reviewed by the auditors. The “After” columns represent the effects after the Transaction. The “Change %” columns compares the “After” columns to the “Before” columns. The number and weighted average number of shares in issue have been stated net of treasury shares. Notes: Extracted from the published interim financial statements for the six months to 31 December 2011. The figures for the Products were derived from the unaudited management accounts of GSK for the six months ended 31 December 2011 and the audited financial statements of GlaxoSmithKline Holdings Pty Ltd for the year ended 31 December 2011. A preliminary assessment has indicated that the intellectual property relating to the Products constitutes indefinite life assets which have been fairly valued in accordance with future expected performance and hence no amortisation has been provided for in the pro-forma financial effects above. Non-recurring transaction costs of R72 million are included in determining the financial effects of which R48 million has been capitalised. The remaining R24 million is excluded in determining the impact of the Transaction on diluted normalised HEPS and represents the only adjustment to diluted HEPS in determining diluted normalised HEPS. Notional interest for the six months ended 31 December 2011 has been provided based on the costs of financing the Transaction. The Products The Products comprise long established pharmaceutical brands of proven performance. The main areas of therapeutic treatment of the Products are analgesic, antibiotics, anti-virals and the central nervous system. Other areas covered include anti-nauseant, anti-inflammatory and muscle relaxants. The leading Products are well recognised brands including Amoxil, Augmentin, Imigran, Kapanol, Lamactil, Mesasal, Timentin, Valtrex, Zantac and Zofran. The Products which are the subject of the Transaction recorded revenue of AUD 127.4 million during the year ended 31 December 2011. During that period Valtrex came off patent and faced generic competition which has subsequently intensified. Some of the Products have also been subject to the Australian Government’s mandatory annual price cuts based on competitive discounting to pharmacy. These price reductions are likely to continue resulting in the revenue expected to be generated by the Products declining over time. The impact of these factors is illustrated by the Products generating revenue in the six months to 30 June 2012 of AUD 47.4 million (six months to 30 June 2011: AUD 70.2 million). Rationale The Products acquired through the Transaction represent an excellent fit with Aspen’s existing portfolio and the added revenue will strengthen Aspen’s position as one of the leading pharmaceutical companies in Australia. Whilst the Products received little promotional focus from GSK, Aspen is confident that it will be able to leverage its proven ability to reinvigorate older brands and the Products’ considerable brand equity in order to enhance the value of the portfolio. Aspen expects the Transaction to be earnings accretive in the year ending 30 June 2013. Small Related Party Transaction GSK is an 18.6% shareholder of Aspen Holdings and is a related party to Aspen Holdings in terms of the JSE listings requirements. BDO Corporate Finance (Pty) Ltd, as the independent professional expert, has confirmed that the value of the Transaction is fair to the shareholders of Aspen Holdings and their fairness opinion is available for inspection at Aspen Holdings’ registered office for a period of 28 days from the date of this announcement. Durban 15 August 2012 Sponsor: Investec Bank Limited The Standard Bank of South Africa Limited Sole Underwriter and Mandated Lead Arranger

Judy Dlamini, Aspen Chairman’s Upper Echelon interview

“I actually want to work until the very last day of my life”, Judy Dlamini ALEC HOGG: Upper Echelon is brought to you by Deloitte – for innovative thinking and thorough strategic planning turn to Deloitte. In our Upper Echelon this week, Judy Dlamini, chair of Mbekani Investment Holdings and better known through her chair of Aspen Pharmacare, one of the hottest stocks on the JSE. In fact, since 2007 when you took over as chair there, Judy, the share price has just gone one way and that’s up. That’s always a good thing, one of the top 20 companies in South Africa. I guess that you were made for it though, given that you are a medical doctor by training and then moved into investment banking, then into entrepreneurship but let’s go back a little bit. Going through your CV I saw Vryheid came up there, Vryheid High or certainly the fact that you did your high schooling there, how did that work in? JUDY DLAMINI: Actually interesting that you could dig that out, it’s an interesting story, I met my husband when I was at Marianhill High School and the plan was that I would do matric at Marianhill High School but the nuns were not too happy with me going out with my husband then. They had this system that they would say you can come back to do matric but we just need your dad to come so that we can talk to him and my dad was very strict. So I went back home, I said, dad, I don’t want to go back there, the maths is not so great. So my dad the whole of November, December he was looking for a school and he found Vryheid, so that’s how I ended up there. ALEC HOGG: That’s incredible, which school in Vryheid? JUDY DLAMINI: Vryheid State High School, not Inkamana because it was so late, the application was quite late and you get space but not for a maths and science class. I used to say to my dad it’s maths or nothing because I knew what maths could do for you. ALEC HOGG: That’s a fabulous story and, of course, your husband Sizwe Nxasana is well known in his own right but you’ve been a little bit in his shadow, Judy. It was interesting to look through here, Discovery Holdings, you were on their board, I guess when there was a split with FirstRand, they might have felt [they] didn’t really want a competitor to be on the board and I guess it’s in your family, you must be one and the same? JUDY DLAMINI: Not really, that’s not how it worked out. I just felt that I had too much on my plate. So every five years I actually look at the portfolio and then I’ll actually say no, I need to come off this board and focus on other things. So that was the reason really and I love low profile, I guess it’s just the personality. Maybe it’s the medical training, doctors are more your one on one people than people who love the podium. ALEC HOGG: What took you out of medicine into investment banking first and then into the entrepreneurial environment? JUDY DLAMINI: I wanted to be a doctor from the age of four, I always wanted to be a doctor and I loved it but I lost the passion, maybe because there was crime involved in my practice and something in me died. Maybe also I just felt I wanted more, I just needed my brain to be stimulated more. As a medical doctor I just felt that your view in life tends to be a bit myopic and then I decided to go to business school and did an MBA, which broadened the horizon, it actually…you know a little bit of something in every field, which for me was ideal. Ja, so the losing of passion was good because then it actually broadened the way I view things. ALEC HOGG: And ignited new passions. JUDY DLAMINI: Oh yes. ALEC HOGG: Business, growing up was it something that did appeal to you? JUDY DLAMINI: I had this focus of being a medical doctor but on the side there was the element of business because my father wasn’t highly educated, actually he had hardly any education but he was an entrepreneur, he ran his small painting contractor company and maybe from that. My mother was a primary school teacher, which is actually just streamline professional but my father is, I guess, where I got the business and the entrepreneurial keenness from. ALEC HOGG: How do you and Sizwe get this life balance or work-life balance? I asked him the same question, when we spoke a little while ago, in this same series of Upper Echelon, I’d love to hear your input? JUDY DLAMINI: We make the effort, Alec. You have to make the effort, you never get the balance right but we try, we always try. I was just talking earlier on that last week he had a meeting in London and I organised my diary that I actually joined him so that we had two extra days to spend with each other. We just take the time to spend with each other and also with [our] children. So let’s just say it’s our priority, it’s the main priority, family and then work. ALEC HOGG: It hasn’t been all plain sailing, we were all very saddened when Sifiso passed away. Was there anything in his passing, your son, that has maybe changed the way you look at things? I ask this because I share that experience as well and it’s not something that easily sits with one, they never go away and it is a… JUDY DLAMINI: It doesn’t, it’s still very fresh as you can imagine and I’ve had a lot of pain in the past, it’s just the worst. ALEC HOGG: Judy, but the contribution… Continue reading Judy Dlamini, Aspen Chairman’s Upper Echelon interview

Aspen businesses activate 29 Mandela Day projects globally

Durban: Aspen, one of the world’s top 10 generic pharmaceutical companies by revenue and the largest pharmaceutical manufacturer in the southern hemisphere, is activating 29 projects across 11 countries on 6 continents in celebration of 2012 Nelson Mandela International Day (“Mandela Day”). Stephen Saad, Aspen Group Chief Executive said, “We have embraced Mandela Day across a number of our businesses globally and we’re committed to making a significant difference in the lives of underprivileged communities on this special occasion. In order to ensure that many communities benefit beyond July 18, some of the worthy recipients that have been identified will become long term CSI beneficiaries of the respective businesses.” “We are extremely proud of Aspen’s employees around the world who have engaged wholeheartedly in the campaign and who will be spending many hours making a difference in the lives of less fortunate communities. An extensive range of activities will be taking place during the forthcoming week including building a house; restoring a class room; painting, repairing and refurbishing children’s homes; planting gardens; creating safe play areas; feeding the hungry; gifting toys, clothes and educational supplies; caring for the elderly and destitute and much more. This is the true spirit of a caring company that lives its values by reaching out to those who are less fortunate.” Aspen’s support of Mandela Day will be demonstrated in Australia, Philippines, Dubai, Mauritius, Germany, Tanzania, Kenya, South Africa, Brazil, Mexico and Venezuela. The majority of the beneficiaries selected receive no grants or support from their local governments and are primarily dependent upon the community for sustenance. A range of projects have been embraced. The Aspen Australia team are working closely with Foodbank and Oxfam, Aspen Philippines is linking up with The House of Refuge in Marikina and Aspen Health Care in Dubai is supporting Médecins Sans Frontières. Aspen Bad Oldesloe in Germany is managing five beneficiaries that include St Josefs Children’s Home, SterniPark Children’s Home, OASE Multiple Generation House, Wichern Retirement Home and Ronald McDonald House in Lubeck. The Aspen Global team in Mauritius selected three separate institutions within Foyer Namaste which provides care for some 50 underprivileged children and young adults who are abandoned, handicapped or have intellectual deficiencies. Beta Healthcare is supporting the Havira Children’s Home and Aga Khan Hawkers Market programme in Kenya while Shelys in Tanzania have pledged support for the Chakuwama Children’s home, Kigamboni Shelter and Mpambano Women’s Group in Dar es Salaam. Aspen’s South African businesses have selected nine worthy beneficiaries. These include Habitat for Humanity in Orange Farms; Bulamahlo Home in Tembisa; Ekusizaneni Children’s Home in Kwa Mashu; Sange Child and Youth Centre in East London; the Missionvale Care Centre, Sinethemba Children’s Home and Echo Foundation that are all located in the Port Elizabeth area; and the Casa Mia Pre-Primary School and Tehillah Community Centre for abused and destitute women and children in Cape Town. The offices in Latin America are also participating in this day of goodwill. Aspen Pharma in Brazil is supporting the Cidade de Deus project for underprivileged children while Aspen Venezuela is reaching out to some 250 orphaned, abandoned or HIV/Aids positive children from Asociación Benefactora de Ayuda al Niño Sin Asistencia in Caracas. Aspen Labs in Mexico is supporting the Toluca-based Escuela Hogar del Perpetuo Socorro, a foster home for abandoned children who are victims of family disintegration and domestic violence. Aspen has a long-standing heritage of CSI commitment to less priviledged communities and this ethos has been incorporated into the business practices of its offices globally. For more information about Aspen’s 2012 Mandela Day activities, click on the dedicated link on aspenpharma.com. Activity progress will be uploaded as it becomes available.

Update on the reported key anti-retroviral (ARV) Tenofovir (TDF) public sector supply shortages

Johannesburg – over the past days and weeks, there have been widespread reports from various State Clinics, in certain provinces, that patients have been unable to access supplies of TDF, a key ARV, used primarily in first line HIV treatment. Due to the negative consequences on both patients and the sustainability of South Africa’s Public ARV programme, Aspen as the contracted supplier for 70% of the TDF volume to the State, takes these reports extremely seriously. In these reports, there has been some suggestions that contracted suppliers have been unable to supply TDF timeously, or in the required quantities. To this end, Aspen is unable to comment on other contracted suppliers of TDF, it does however wish in the clearest terms, to confirm its own supply position as follows: Aspen has met and exceeded, both the timing and required quantity for TDF under the terms of its State contract, which requires it to supply 70% of the TDF volumes; In terms of the contract, Aspen is required to supply TDF within 6 weeks from receipt of orders; January 2012 represented the first month that Donor procured TDF had been depleted and the Department of Health (DOH) returned to normal procurement from its tender Contractors; Accordingly, having regard for its 70%, 6 weeks contractual supply obligation, Aspen would have been required to supply 3,33million TDF packs by the end of June 2012. Aspen confirms that it will have delivered 4,2million packs, or 126% of its required volume during this period; Aspen has met and has had to exceed its supply requirements, as shortages from other suppliers have manifested. In response to these shortages, Aspen has swiftly and through considerable resource application scaled up its manufacturing capacity to ensure the supply of 1,13million TDF packs in May 2012, which exceeds the entire May 2012 TDF public sector requirement. Aspen is also able to supply 1,2million TDF packs in June 2012, which exceeds the entire TDF public sector requirement for the month of June 2012; and Aspen can confirm that it presently has no backorders for TDF, meaning that no orders in the system exceed the contractual 6 week delivery period. On this basis, Aspen continues to view supply security and the maintenance of the integrity of the South African Public ARV programme as a national imperative. Aspen also views timeous ARV delivery at the required quantities as non-negotiable. To this end, Aspen will continue its excellent track record of meeting its ARV supply commitments and where possible to step in and commit its manufacturing capacity where other suppliers are unable to supply a part or all of their supply commitments. In the current tender, which commenced on 1 January 2011, Aspen has stepped in and supplied 3 other ARV medicines in addition to TDF, where other suppliers had experienced supply constraints.

To rest is to rust : Financial Mail Wonderful Weekend

In my youth I imagined that I would be a professional sportsman or a game ranger. It hasn’t turned out that way, but I don’t have any regrets about the choices I have made. I believe you have to take advantage of the opportunities that are presented to you and adapt if and when necessary. Family, friends and health are the three most important aspects of my life. I have learnt that balance is so important in life, and that includes my family, with religion also being an influence. My wife and four daughters have taught me that there is no messing with the big five — they are my top priority. Durban offers us an incredible lifestyle in our beautiful country and my perfect weekend is about spending time outdoors with my family and friends. Kirkmans and Exeter in the Sabi Sands Game Reserve are my favourite getaway destinations. We escape regularly to nature, which really refreshes us. Limited cellphone contact is allowed and this applies especially to our kids! During our time away I catch up with the most important people in my life. It is then that I try to pass on the values of humility and respect and we try to satisfy ourselves that we are doing the very best we can in all aspects of our lives. I believe in the saying that “to rest is to rust”, which has become our family motto. Sport is important to me and I make time to ensure that I exercise regularly as this makes for a healthy mind and a balanced lifestyle. I was a keen rugby player many years ago and I still really enjoy the game, but there comes a time when you have to admit that your body isn’t made for the knocks that you’re bound to take on the field. So I choose to support the Springboks and the Sharks from the sideline. I am an avid cyclist and I recently participated in the Aspen Trans Karoo 240km mountain bike challenge to raise funds for paediatric health care in SA. I was honoured to have the health minister, Dr Aaron Motsoaledi, at the starting line alongside me. This was a demonstration of his support for public-private partnerships to establish and enhance local paediatric hospitals. The ride took 16 hours. It was exhausting but at R40000/ km I dared not stop! A number of local and offshore businesses were approached to help me raise funds for the Nelson Mandela Fund and the KwaZulu Natal Children’s Hospitals and we’ve already passed the R10m mark. But more needs to be done. So this is a challenge to large corporates to follow the minister’s example and to embrace the need for quality paediatric health care and to make a difference for the children through the trust that has been established for this cause. When we started Aspen in 1997 it was intended to be a small company without manufacture, but it has grown to where it has now been ranked as the best-performing JSE blue chip stock over the past six months. This is great for team morale and proves that Aspen’s hard work is paying off. I am at a point in my life where I feel I still have a big contribution to make. Some day I would like to be remembered by my family and friends for being a good father, husband and friend. Professionally, I’d like to leave a mark as someone who made a meaningful difference to health care on the continent — in particular if our efforts result in a positive impact for my country and the African region in combating HIV/Aids, tuberculosis and malaria. A vaccine discovery for these diseases would be first prize. SA has so much potential and the best advice I could share with our youth is to harness that potential to its fullest. If you combine that mind-set with a sound education and an entrepreneurial spirit, you will have a good start in life.

30 000 ARV packs delivered in Limpopo

Following discussions between the health Minister Dr Aaron Motsoaledi and Aspen Pharmacare Senior Executive Mr Stavros Nicolaou in Johannesburg, Aspen Pharmacare released 30 000 packs of Tenofovir (TDF) for the Limpopo depot earlier today. Further releases to this province are expected during the course of next week. Aspen Pharmacare is one of the two (2) companies supplying ARVs to government hospitals. Reports have recently suggested that there were shortages that were being encountered in the availability of ARVs. In a media conference in Johannesburg yesterday, the health Minister dispelled these reports of complete unavailability of these drugs, indicating instead that there was a decline in stock-levels which did not necessarily translate in patients not getting their ARVs. Health Minister has expressed his happiness at news that stock-levels in the Limpopo depot have been increased. “It’s an important development and it actually demonstrates our commitment to ensuring that at no point are our patients compromised. We are continuously monitoring the situation on a daily basis and I must commend Aspen for their quick response in dealing with the situation”, said the health Minister. For media enquiries please contact: Fidel Hadebe – Department of Health: 079 517-3333 or Stavros Nicolaou – Senior Executive: Aspen Pharmacare: 082 458-3135. Issued by the Department of Health

Statement by Aspen on the reported Tenofovir (TDF) public sector supply shortages

Statement by Aspen on the reported Tenofovir (TDF) public sector supply shortages Johannesburg: Since March this year there have been sporadic reports of Tenofovir (TDF) supply shortages in certain provinces and hospitals where patients are receiving ARV treatment. These reports seem to have manifested again this week and some allegations have emerged that the contracted TDF suppliers are in part responsible for these shortages. Aspen, as the Southern Hemisphere’s largest Pharmaceutical Manufacturer and the leading supplier of ARV’s to both the SA private and public sector can in no way condone these shortages, even if it is to a small group of patients and accordingly the company wishes to publicly clarify the following: • At a press briefing earlier today Minister of Health, Dr Aaron Motsoaledi confirmed that the National Department of Health (NDOH) had checked all 10 depots nationally and all 10 have TDF. • Aspen has the state contract to supply 70% of the required state volume for TDF for a two year period, commencing on 1 January 2011 and ending on 31 December 2012. It is required to deliver within 6 weeks of confirmation of received orders. • Initial offtakes for TDF during the first year of the tender contract were extremely low, with monthly orders placed on Aspen averaging around 250 000 monthly treatment packs. This was largely because donor fund procured TDF product displaced much of the tender volumes. • This donor fund procured inventory ran out by December 2011 and it became necessary for the current suppliers to respond, by immediately scaling up production. • The transition from donor stock to state procured TDF was not a smooth transition, with some provinces and institutions underforecasting demand and/or placing orders either erratically or only once stock levels had dwindled significantly. Consequently, some institutions remained well stocked, whilst others ran into problems. • Despite this, For example, NDOH’s forecast for 70% of the volume over the past 3 months from March to May 2012 required Aspen to supply 668 000 packs per month or 2 million packs for this period. Over this 3 month period, Aspen has supplied 2,4 million packs, exceeding its contractual requirement by more than 400 000 packs. This averages out to approximately 860 000 packs per month. Aspen has been advised by the NDOH that it is needed to over-supply on its contractual commitment because the supplier required to supply the other 30% of the TDF tender is unable to do so. Aspen has accordingly stepped in and is manufacturing in excess of its contractual requirements. By way of example, Aspen has supplied 1,140 million treatment packs for the month of May to the NDOH, exceeding by 350 000 packs its monthly contractual requirement. • As this crisis began to unfold, Aspen acting in consultation with the NDOH, has been able to step up both its raw material imports and allocation of manufacturing capacity to meet this increased demand. It has been able to do so with requisite flexibility and in a short space of time. • Given the current situation, Aspen will continue to commit the required capacity from now until the end of the tender period, to ensure that it not only meets its own tender volume obligations, but it is able to step in and supply the quantities that other suppliers are unable to. • Aspen views supply security and the maintenance of the integrity of the South African Public ARV programme as a National imperative. It also views its commitment to supply timeously and according to its committed quantities with equal importance. To this end, Aspen has an excellent track record in the manufacture, supply and delivery of ARV’s to the SA Government. This is not the first time Aspen has had to step in to supply where importers who had won the contract for other ARVs have been unable to supply in the current contract period. This has been the case, for example, where Aspen has had to take over supply for Stavudine 30mg and Lamivudine 150mg in the current two year contract period. Aspen has thus continued to supply on its own commitments, in addition to that where other suppliers have been unable to supply. In conclusion, Aspen is able to confirm that it is presently meeting both its contractual terms and supply volumes for TDF that it is required to in terms of the current ARV tender. The Company can also confirm that it presently has no backorder for TDF, meaning that all remaining orders in the system are within the 6 week delivery period. The company will supply around 1,1 million packs in June 2012, which will again exceed monthly NDOH forecast by 400 000 units.

Stephen Saad raises R10 million for children

Health Minister supports Stephen Saad’s initiative as he raises R10m for children Durban: Health Minister Dr Aaron Motsoaledi’s support of the Sifiso Nxasana Paediatric Trust for the Children of Africa (“the Trust”), which is raising funds for paediatric hospitals, is paying off with R10 million already raised. The campaign was recently launched by pharmaceutical entrepreneur Stephen Saad, Aspen Group Chief Executive, as a personal commitment to making a quality healthcare difference for all children. Dr Motsoaledi demonstrated his support of the campaign by leading the field of cyclists alongside Saad in the inaugural 240 km Aspen Trans Karoo mountain bike challenge from Ceres to Sutherland in the Western Cape. Saad said “The Minister’s commitment to establishing and enhancing healthcare facilities for children has been amazing. His enthusiastic participation in the event proves that he truly cares about their needs and he demonstrated this with his peddling power.” Dr Motsoaledi supports the urgent need for public-private partnerships in addressing the shortage of paediatric healthcare. “The challenges confronting us are huge and government alone cannot adequately address them. We are glad that Aspen has identified this gap and are sharing our vision of ensuring that all children, regardless of their socio-economic status have access to quality paediatric care in our country”, said the health Minister. “We have an obligation to care for our children and we’re calling on local and offshore businesses who have an interest in Africa to support the Trust. We’re grateful for the pledges of R10 million received so far and I’m confident that we can raise so much more,” said Saad who has challenged big businesses to follow the Health Minister’s lead and make a meaningful paediatric difference through the Trust. Saad completed the race just short of 16 hours and said that it was a fabulous feeling to cross the finish line, knowing that his efforts would make a huge healthcare difference for children. Former South African Iron Man Raynark Tissink won the race with Hannele Steyn being the first lady to cross the finish line. The 18½ hour race route reached its highest point at 185km, with a 724m climb over 6km on a 12% gradient. South Africa needs more paediatric hospitals. There are only 4 in Africa to serve some 450 million children. The only such facility in South Africa is the Red Cross Children’s Hospital in Cape Town. Canada has 23, Australia has 19 and there are 20 in Germany. The two primary beneficiaries of the Trust have been identified as the Nelson Mandela Children’s Hospital and the Kwa-Zulu Natal Children’s Hospital. The Trust was established to support the Long Ride for Sifiso Campaign following the untimely passing of Sifiso Nxasana, son of Judy Dlamini and her husband Sizwe Nxasana, CEO of FirstRand Ltd. Judy is the Chairman of Aspen. To support the Trust, download and complete the Sifiso Nxasana Long Ride Campaign pledge form on www.transkaroomtb.co.za.

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below:

Human Capital
Legal

Supply Chain

Treasury
Ethics & Compliance
Risk & Sustainability
Digital Technology

Tax